← Back to patent-cliff list
CAS 108-21-4
isopropyl acetate
Codes: RISD-033, ESOME-019, CENSA-019
Application context (from source-drug indications)
Spinal muscular atrophyRisdiplamHeartburnEsomeprazole Magnesium HydrateGastro-oesophageal reflux diseaseEsomeprazole Magnesium HydrateDuodenal ulcerEsomeprazole Magnesium HydrateGastric ulcerEsomeprazole Magnesium HydratePeptic oesophagitisEsomeprazole Magnesium HydrateHelicobacter pylori infectionEsomeprazole Magnesium Hydrate进行性核上性麻痹CensavudineFrontotemporal dementiaCensavudineAmyotrophic lateral sclerosisCensavudineAicardi综合征CensavudineHIV infectionCensavudine
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Risdiplam | Tier B — Position early | - |
| Esomeprazole Magnesium Hydrate | Tier B — Position early | - |
| Censavudine | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-aminocyclopropanecarboxylic acid→ethyl 1-aminocyclopropanecarboxylate hydrochloride→2-chloroacetyl chloride→ethyl 1-(2-chloroacetamido)cyclopropanecarboxylate→7-benzyl-4,7-diazaspiro[2.5]octane-5,8-dione→7-benzyl-4,7-diazaspiro[2.5]octane→tert-butyl 7-benzyl-4,7-diazaspiro[2.5]octane-4-carboxylate→oxalic acid→tert-butyl 4,7-diazaspiro[2.5]octane-4-carboxylate hemioxalate→tert-butyl 4,7-diazaspiro[2.5]octane-4-carboxylate→5-bromo-2-chloropyridine→tert-butyl 7-(6-chloropyridin-3-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate→tert-butyl 7-(6-aminopyridin-3-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate→di-tert-butyl malonate→tert-butyl 7-(2-hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate→tert-butyl 7-(4-oxo-2-(tosyloxy)-4H-pyrido[1,2-a]pyrimidin-7-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate→2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine→tert-butyl 7-(2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-7-yl)-4,7-diazaspiro[2.5]octane-4-carboxylate→6-chloropyridazin-3-amine→4-bromo-6-chloropyridazin-3-amine→6-chloro-4-methylpyridazin-3-amine→isopropyl acetate→6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine
5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole→sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide→[1,1'-binaphthalene]-2,2'-diol→[1,1'-binaphthalene]-2,2'-diol compound with 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole (1:1)→isopropyl acetate
5-methylpyrimidine-2,4(1H,3H)-dione→isopropyl acetate→acrylaldehyde→isopropyl 3-hydroxypent-4-enoate→isopropyl 3-(methoxymethoxy)pent-4-enoate→isopropyl 4,5-dihydroxy-3-(methoxymethoxy)pentanoate→isopropyl 5-((tert-butyldimethylsilyl)oxy)-4-hydroxy-3-(methoxymethoxy)pentanoate→isopropyl 5-((tert-butyldimethylsilyl)oxy)-3-(methoxymethoxy)-4-oxopentanoate→ethynylmagnesium bromide→isopropyl (3S,4R)-4-(((tert-butyldimethylsilyl)oxy)methyl)-4-hydroxy-3-(methoxymethoxy)hex-5-ynoate→(4S,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyl-4-(methoxymethoxy)tetrahydrofuran-2-ol→(4S,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyl-4-(methoxymethoxy)tetrahydrofuran-2-yl acetate→1-((2R,4S,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyl-4-(methoxymethoxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione→1-((2R,4S,5R)-5-ethynyl-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione→1-((2R,4S,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5-ethynyl-4-hydroxytetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione→(2R,3S,5R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-2-ethynyl-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl methanesulfonate→1-((2R,5R)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 4-Boc-4,7-diazaspiro[2.5]octane Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.